Tinzaparin

Enoxaparin sodium Dalteparin sodium Tinzaparin Nadroparin sodium Ardepatrin Benzylation followed by alkaline depolymerization Nitrous acid depolymerization Enz3miatic depolymerization with heparinase Nitrous acid depolymerization Peroxidative depolymerization... [Pg.139]

Investigators. Tinzaparin in acute ischemic stroke (TAIST) a randomised aspirin-controUed trial. Lancet 2001 358 702-710. [Pg.158]

Dalteparin or tinzaparin—1 mg protamine/100 units dalteparin or tinzaparin to a maximum of 50 mg... [Pg.98]

Dose may depend on the lapsed time after LMWH administration (e.g., 0.5 mg protamine per 100 units dalteparin or tinzaparin to a maximum of 50 mg if >8 h has passed since the last administered dose)... [Pg.98]

Moderate Major or minor surgery, age 40-60 years, and no clinical risk factors Major surgery, age less than 40 years, and no clinical risk factors Minor surgery, with clinical risk factor(s) Acutely ill (e.g., myocardial infarction, ischemic stroke, heart failure exacerbation), and no clinical risk factors 10-20 1-2 I o UFH 5000 units SC every 12 hours Dalteparin 2500 units SC every 24 hours Enoxaparin 40 mg SC every 24 hours Tinzaparin 3500 units SC every 24 hours IPC Graduated compression stockings... [Pg.140]

Tint trials, 19 384 Tin vanadium yehow cassiterite formula and DCMA number, 7 347t Tinzaparin, 4 95t, 5 175... [Pg.951]

Low-molecular-weight heparin (average MW -5000) has a longer duration of action and needs to be given only once daily (e.g., certoparin, dalteparin, enoxaparin, reviparin, tinzaparin). [Pg.146]

Thiopental Thio-TEPA Thrombin Thyroxine Tiagabine Ticarcillin Ticlopidine Timolol Tinidazol Tinzaparin ... [Pg.348]

Cheer MC, Dunn CJ, Foster R. Tinzaparin sodium. A review of its pharmacology and clinical use in the prophylaxis and treatment of thromboemboUc disease. Drugs 2004 64 1479-1502. [Pg.82]

TINZAPARIN Evaluate all patients for bleeding disorders before administration of tinzaparin. [Pg.120]

Adults - The recommended dose for the treatment of DVT with or without PE is 175 anti-Xa units/kg of body weight, administered subcutaneously once daily for at least 6 days and until the patient is adequately anticoagulated with warfarin (INR at least 2 for 2 consecutive days). Initiate warfarin sodium therapy when appropriate (usually within 1 to 3 days of tinzaparin initiation). [Pg.120]

As tinzaparin may theoretically affect the prothrombin time (PT)/INR, draw blood for PT/INR determination just prior to the next scheduled dose of tinzaparin for patients receiving tinzaparin and warfarin. [Pg.120]

The following table provides tinzaparin doses for the treatment of DVT with or without PE. It is necessary to calculate the appropriate tinzaparin dose for patient weights not displayed in the table. [Pg.120]

Use an appropriately calibrated syringe to assure withdrawal of the correct volume of drug from tinzaparin vials. ... [Pg.121]

Tinzaparin Weight-Based Dosing for Treatment of DVT With or Without Symptomatic PE... [Pg.121]

Use the following equation to calculate the volume (mL) of tinzaparin 175 anti-Xa units/kg subcutaneous dose for treatment of DVT ... [Pg.122]

Pharmacology Enoxaparin, tinzaparin, and dalteparin are LMWHs. These agents enhance the inhibition of Factor Xa and thrombin by binding to and accelerating antithrombin activity. They preferentially potentiate the inhibition of Factor Xa, while only slightly affecting thrombin and clotting time (activated partial thromboplastin time [APTT] or PT). [Pg.123]

Hypersensitivity to LMWHs, heparin, or pork products hypersensitivity to sulfites or benzyl alcohol (multidose vials) history of heparin-induced thrombocytopenia (tinzaparin) active major bleeding thrombocytopenia associated with positive in... [Pg.123]

Thrombocytopenia The incidence of thrombocytopenia with platelet counts between 50,000/mm and 100,000/mm was 1.3% in patients treated with enoxaparin, 1% with tinzaparin, and less than 1% with dalteparin. Severe thrombocytopenia (platelet count below 50,000/mm ) occurred in 0.13% of tinzaparin-treated patients and 0.1% of enoxaparin-treated patients. [Pg.124]

Priapism Priapism has been reported from postmarketing surveillance of tinzaparin as a rare occurrence. In some cases, surgical intervention was required. Renal/Hepatic function impairment Delayed elimination of LMWHs may occur with severe liver or kidney insufficiency. Use with caution. [Pg.124]

Elderly Delayed elimination of enoxaparin and tinzaparin may occur. [Pg.124]

Benzyl alcohol The multiple-dose vials of dalteparin, enoxaparin, and tinzaparin contain benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal gasping syndrome in premature infants. Because benzyl alcohol may cross the placenta, do not use LMWHs preserved with benzyl alcohol in pregnant women. Thromboembolic events If thromboembolic events occur despite LMWH prophylaxis, discontinue and initiate appropriate therapy. [Pg.125]

Protamine generic Tinzaparin (Innohep) Warfarin (Coumadin)... [Pg.50]

See also in sourсe #XX -- [ Pg.59 ]

See also in sourсe #XX -- [ Pg.304 , Pg.305 ]

See also in sourсe #XX -- [ Pg.367 ]

See also in sourсe #XX -- [ Pg.244 ]

See also in sourсe #XX -- [ Pg.304 ]

See also in sourсe #XX -- [ Pg.350 ]

See also in sourсe #XX -- [ Pg.477 ]

See also in sourсe #XX -- [ Pg.200 ]

See also in sourсe #XX -- [ Pg.29 , Pg.31 ]

See also in sourсe #XX -- [ Pg.227 ]

See also in sourсe #XX -- [ Pg.953 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...